TIDMABC
RNS Number : 3972Y
ABCAM PLC
02 January 2020
2 January 2020
ABCAM PLC
("Abcam" or "the Group")
Completion of transaction between Abcam and Expedeon
Abcam plc (AIM LSE: ABC), a global leader in the supply of life
science research tools, today announces that the transaction to
acquire Expedeon Ltd, Innova Biosciences Ltd. and TGR BioSciences
(the "Proteomics and Immunology business") from Expedeon AG
("Expedeon") (the "Acquisition") has now completed.
As announced in November 2019, the Acquisition secures a
complementary portfolio of leading protein conjugation technologies
and products for Abcam, including well-known industry brands
Lightning-Link(R) and CaptSure(TM) .
Commenting on the completion of the Acquisition, Alan Hirzel,
CEO of Abcam, said:
"We are delighted to have completed this transaction and welcome
our new colleagues to Abcam. Expedeon's portfolio of products and
technology, combined with Abcam's antibody and protein strengths,
place us well to address the growing need for antibody conjugation
and multiplexing solutions."
Ondra LLP provided advice to the Board of Directors of Abcam in
relation to this transaction.
For further information, please contact:
Abcam
+ 44 (0) 1223 696 000
Alan Hirzel, Chief Executive Officer
Gavin Wood, Chief Financial Officer
James Staveley, VP Investor Relations
J.P. Morgan Cazenove - Nominated Advisor and Joint Corporate
Broker
+44 (0) 20 7742 4000
James Mitford / Hemant Kapoor
Numis - Joint Corporate Broker
+44 (0) 20 7260 1000
Garry Levin / Duncan Monteith
FTI Consulting (Media enquiries)
+44 (0) 20 3727 1000
Ben Atwell / Natalie Garland-Collins
Ondra LLP, which is authorised and regulated by the Financial
Conduct Authority in the United Kingdom, is acting solely for the
Board of Directors of Abcam and no one else in connection with the
matters described in this announcement and will not be responsible
to anyone other than the Board of Directors of Abcam for providing
the protections afforded to clients of Ondra LLP, nor for providing
advice in relation to this announcement. Neither Ondra LLP nor any
of its respective subsidiaries, branches or affiliates owes or
accepts any duty, liability or responsibility whatsoever (whether
direct or indirect, whether in contract, in tort, under statute or
otherwise) to any person who is not a client of Ondra LLP in
connection with this announcement or any matter referred to
herein.
Forward looking statements
This announcement, including any information included or
incorporated by reference in this announcement, may contain
forward-looking statements (including words such as "believe",
"expect", "estimate", "intend", "anticipate" and words of similar
meaning) which are based upon current expectations and assumptions
regarding anticipated developments and other factors affecting the
Abcam Group. All statements other than statements of historical
facts may be forward-looking statements and should not be treated
as guarantees of future performance. These forward-looking
statements involve risks and uncertainties, many of which are
beyond the control of the Abcam Group, and there are important
factors that could cause actual results to differ materially from
those expressed or implied by these forward-looking statements.
These forward-looking statements speak only as at the date of this
announcement and accordingly undue reliance should not be placed on
such statements. The Abcam Group does not assume any obligation to,
and does not intend to, revise or update these forward-looking
statements, except as required pursuant to applicable law.
About Abcam plc
As a global life sciences company, Abcam identifies, develops,
and distributes high-quality biological reagents and tools that are
crucial to research, drug discovery and diagnostics. Working across
the industry, the Company supports life scientists to achieve their
mission, faster.
Abcam partners with life science organisations to co-create
novel binders for use in drug discovery, in vitro diagnostics and
therapeutics, driven by the Company's proprietary discovery
platforms and world-leading, antibody expertise.
By constantly innovating its binders and assays, Abcam is
helping advance the global understanding of biology and causes of
disease, which enables new treatments and improved health. The
Company's pioneering data-sharing approach gives scientists
increased confidence in their results by providing validation, user
comments and peer-reviewed citations for its 110,000 products.
With eleven sites globally, many of Abcam's 1,100 strong team
are located in the world's leading life science research hubs,
complementing a global network of services and support. Abcam was
admitted to AIM in 2005 (AIM: ABC).
To find out more, please visit www.abcam.com and
www.abcamplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRBGBDDSBXBGCB
(END) Dow Jones Newswires
January 02, 2020 02:00 ET (07:00 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2024 to May 2024
Abcam (LSE:ABC)
Historical Stock Chart
From May 2023 to May 2024